Corey Fishman Net Worth

The estimated Net Worth of Corey N. Fishman is at least $1.68 Million dollars as of 6 August 2024. Mr. Fishman owns over 82,613 units of Iterum Therapeutics Plc stock worth over $144,600 and over the last 8 years he sold ITRM stock worth over $147,820. In addition, he makes $1,392,030 as Chief Executive Officer and Director at Iterum Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Fishman ITRM stock SEC Form 4 insiders trading

Corey has made over 8 trades of the Iterum Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 82,613 units of ITRM stock worth $87,157 on 6 August 2024.

The largest trade he's ever made was exercising 215,000 units of Iterum Therapeutics Plc stock on 11 March 2022 worth over $226,825. On average, Corey trades about 20,407 units every 113 days since 2016. As of 6 August 2024 he still owns at least 137,062 units of Iterum Therapeutics Plc stock.

You can see the complete history of Mr. Fishman stock trades at the bottom of the page.

Corey Fishman biography

Corey N. Fishman serves as Chief Executive Officer, Director of the Company. From August 2010 to February 2015, Mr. Fishman served as chief operating officer of Durata Therapeutics, Inc., a pharmaceutical company acquired by Actavis plc, a pharmaceutical company, and he also served as chief financial officer of Durata Therapeutics, Inc., from June 2012 to February 2015. From 2008 to 2010, Mr. Fishman served as chief financial officer of GANIC Pharmaceuticals, Inc., a pharmaceutical company. From 2002 to 2008, Mr. Fishman served in a variety of roles at MedPointe Healthcare, Inc., a specialty pharmaceutical company acquired by Meda AB, including as chief financial officer from 2006 to 2008. Mr. Fishman currently serves as a member of the boards of directors of Momenta Pharmaceuticals, Inc., a biotechnology company and BioSpecifics Technology Corporation, a biopharmaceutical company. Mr. Fishman holds a B.A. in economics from the University of Illinois at Urbana-Champaign and an M.S.M. in finance from the Krannert School of Management at Purdue University.

What is the salary of Corey Fishman?

As the Chief Executive Officer and Director of Iterum Therapeutics Plc, the total compensation of Corey Fishman at Iterum Therapeutics Plc is $1,392,030. There are no executives at Iterum Therapeutics Plc getting paid more.

How old is Corey Fishman?

Corey Fishman is 55, he's been the Chief Executive Officer and Director of Iterum Therapeutics Plc since 2015. There are 5 older and 7 younger executives at Iterum Therapeutics Plc. The oldest executive at Iterum Therapeutics Plc is Dr. Michael W. Dunne M.D., 61, who is the Strategic Advisor & Director.

What's Corey Fishman's mailing address?

Corey's mailing address filed with the SEC is C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE, DUBLIN 2, L2, .

Insiders trading at Iterum Therapeutics Plc

Over the last 6 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital..., and James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.

What does Iterum Therapeutics Plc do?

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.

Complete history of Mr. Fishman stock trades at Biospecifics Technologies, Momenta Pharmaceuticals, and Iterum Therapeutics Plc

Iterum Therapeutics Plc executives and stock owners

Iterum Therapeutics Plc executives and other stock owners filed with the SEC include:

• Corey Fishman,
  Chief Executive Officer, Director
• Corey N. Fishman,
  Pres, CEO & Director
• Michael Dunne,
  Chief Scientific Officer
• Judith Matthews,
  Chief Financial Officer
• Judith M. Matthews,
  Chief Financial Officer
• Dr. Michael W. Dunne M.D.,
  Strategic Advisor & Director
• Dr. Sailaja Puttagunta M.D.,
  Chief Medical Officer
• Brenton Ahrens,
  Independent Interim Chairman of the board
• Shahzad Malik,
  Independent Director
• David Kelly,
  Independent Director
• Ronald Hunt,
  Independent Director
• Patrick Heron,
  Independent Director
• Mark Chin,
  Independent Director
• Dr. Steven I. Aronin M.D.,
  Sr. VP & Head of Clinical Devel.
• Louise Barrett,
  Sr. VP of Legal Affairs & Sec.
• Tom Loughman Ph.D.,
  Sr. VP of Technical Operations
• Beth Hecht,
  Director
• Vijay K Ratcliffe Liam Lathi,
  
• Venture Partners Ix, L.P.Po...,
  
• James Healy,
  Director
• X L.P.Canaan Partners X Llc...,
  
• Paul R Edick,
  Director
• Jeffrey R. Schaffnit,
  Chief Commercial Officer
• Patrick J Heron,
  Director
• Capital Management, L.P.Ra ...,
  
• Healthcare Vii, L.P.Frazier...,
  
• Venture Partners Ix, L.P.So...,
  
• Venture Partners Ix, L.P.So...,
  
• Alexander J Sarissa Capital...,
  
• Sailaja Puttagunta,
  Chief Medical Officer